Rosiglitazone treatment of patients with extreme insulin resistance and diabetes mellitus due to insulin receptor mutations has no effects on glucose and lipid metabolism
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Rosiglitazone, a thiazolidinedione (TZD), increases insulin sensitivity by reducing levels of plasma NEFA, triglycerides (TG), glucose and serum insulin. Rosiglitazone treatment decreases insulin resistance in type 2 diabetic patients, but no data exist concerning rosiglitazone treatment of patients with syndromes of extreme insulin resistance.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Journal of Internal Medicine |
| Vol/bind | 250 |
| Udgave nummer | 5 |
| Sider (fra-til) | 406-14 |
| Antal sider | 9 |
| ISSN | 0954-6820 |
| Status | Udgivet - nov. 2001 |
ID: 92192140